NAC Supplementation and Soccer Specific Performance

August 20, 2020 updated by: Ioannis G. Fatouros, University of Thessaly

Effects of NAC Supplementation on Immune Function, Inflammatory and Performance Responses of Elite Soccer Players Participated in Three Repetitive Games.

In this investigation the investigators utilized NAC supplementation to boost GSH availability during an one-week-microcycle consisting of three soccer games, in order to test the hypotheses that: i) antioxidant supplementation may enhance the recovery of performance and physiological stress variables following multiple match-plays and ii) redox status perturbations are critical in regulating the inflammatory response and repair in skeletal muscle, following repetitive exercise-induced muscle injuries.

Study Overview

Detailed Description

After exercise-induced muscle microtrauma the thiol/disulfide couple of reduced (GSH) and oxidized glutathione (GSSG) is a key regulator of important transcriptional pathways that control the inflammatory response and recovery of skeletal muscle.

The objective was to examine how thiol-based antioxidant supplementation affects the muscle damage, oxidative stress, inflammatory and immune responses, as well as the level of post-game fatigue and muscle's recovery kinetics in response to three soccer games within a week. Participants were randomly assigned to one of four groups: i) Experimental-NAC [EXP-NAC, N=10, participated in daily training sessions and three games and received NAC (20 mg/kg/day)], ii) Experimental-Placebo (EXP-Pla, N=10, participated in daily training sessions and three games and received Placebo), iii) Control-NAC [CON-NAC, N=10, participated in daily training sessions only and received NAC(20 mg/kg/day)] and iv) Control-Placebo (CON-Pla, N=10, participated in daily training sessions only and received Placebo). Blood samples were collected at baseline, post-games and daily during recovery. Performance was assessed at baseline and daily during recovery.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tríkala, Greece, 42100
        • Exercise Biochemistry Laboratory, School of Physical Education & Sports Sciences, University of Thessaly

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 26 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Participation at elite level (top three division leagues) of soccer competition for at least five years
  • Abstained from consumption of performance-enhancing supplements, antioxidant supplements and medications (for at least 6 months before and during the study)
  • Participation in at least six two-hour training sessions and one match per week
  • Non-smokers

Exclusion Criteria:

  • A known NAC intolerance or allergy
  • A recent febrile illness
  • History of muscle lesion
  • Lower limb trauma
  • Metabolic diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: EXP-NAC
Participated in daily training sessions and three games, and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.
Other Names:
  • NAC
Experimental: EXP-Pla
Participated in daily training sessions and three games, and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.
Active Comparator: CON-NAC
Participated in daily training sessions only and supplemented daily with N-acetylcysteine, orally in three daily dosages (morning-midday-evening),for seven consecutive days.
Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.
Other Names:
  • NAC
Active Comparator: CON-Pla
Participated in daily training sessions only and supplemented daily with Placebo, orally in three daily dosages (morning-midday-evening), for seven consecutive days.
500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in total antioxidant capacity in serum
Time Frame: At baseline and daily throughout the study, up to 11 days
At baseline and daily throughout the study, up to 11 days
Change in protein carbonyls in serum
Time Frame: At baseline and daily throughout the study, up to 11 days
At baseline and daily throughout the study, up to 11 days
Change in thiobarbituric acid reactive substances in serum
Time Frame: At baseline and daily throughout the study, up to 11 days
At baseline and daily throughout the study, up to 11 days
Change in reduced glutathione in red blood cells
Time Frame: At baseline and daily throughout the study, up to 11 days
At baseline and daily throughout the study, up to 11 days
Change in oxidized glutathione in red blood cells
Time Frame: At baseline and daily throughout the study, up to 11 days
At baseline and daily throughout the study, up to 11 days
Change in creatine kinase in activity in plasma
Time Frame: At baseline and daily throughout the study, up to 11 days
At baseline and daily throughout the study, up to 11 days
Change in white blood cell count in blood
Time Frame: At baseline and daily throughout the study, up to 11 days
At baseline and daily throughout the study, up to 11 days
Change in repeated sprint ability
Time Frame: At baseline and daily throughout the study, up to 11 days
Players' repeated sprint ability was assessed via a repeared sprint test. Each player performed 5 x 30 meters sprints interspersed by 25 seconds of active recovery. Sprint time was recorded by using infrared photoelectrical gates.
At baseline and daily throughout the study, up to 11 days
Change in high intensity running during the game
Time Frame: During games 1, 2 and 3
High intensity running (i.e. > 14km/h) during the games was monitored by utilizing high time-resolution GPS devices.
During games 1, 2 and 3

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in blood lactate concentration during the game
Time Frame: During games 1, 2 and 3
During games 1, 2 and 3
Change in average heart rate during the game
Time Frame: During games 1, 2 and 3
During games 1, 2 and 3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: IOANNIS G FATOUROS, Ph.D., UNIVERSITY OF THESSALY, SCHOOL OF PHYSICAL EDUCATION & SPORTS SCIENCES

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2016

Primary Completion (Actual)

July 1, 2016

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

June 22, 2020

First Submitted That Met QC Criteria

August 20, 2020

First Posted (Actual)

August 21, 2020

Study Record Updates

Last Update Posted (Actual)

August 21, 2020

Last Update Submitted That Met QC Criteria

August 20, 2020

Last Verified

August 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Skeletal Muscle Performance

Clinical Trials on N-acetylcysteine

3
Subscribe